PHOTO
Dubai: The corona situation is getting worse day by day in the world; lockdown continues in many countries across the globe, and the virus has infected more than 2 million people leaving around 120,000 people dead. Currently, a lot of companies are involved in the development of a coronavirus vaccine. The pharmaceutical companies continue the race to be the first to license a COVID-19 vaccine and some of them have already made great progress, while others are at the very beginning of the race. Every company is using different technology platforms to create experimental vaccines.
Here are the 6 important Biotech stocks that we think the investors should watch now. Gulf Brokers see, however, huge volatility in these stocks as investors will continue to speculate as to whether these companies will, as for the vaccine, come out on top.
Gilead Sciences Inc. (NASDAQ: GILD)
Johnson & Johnson, Inc. (NYSE: JNJ)
GlaxoSmithKline plc. (LON: GSK) and Sanofi (EPA: SAN)
Pfizer, Inc. (NYSE: PFE)
Moderna, Inc. (NASDAQ: MRNA)
Inovio Pharmaceuticals (NASDAQ: INO)
Medical companies worldwide are tirelessly working to develop vaccines and treatment for COVID-19. We expect a further upside strength in the biotech and pharmaceutical sectors during this crisis. But as we know, these experimental drugs are in the early stages and there is no guarantee that these drugs will achieve the FDA approval. The good news is that a number of biotech firms have already received the support of government funding.
Syam K.P.
Chief Analyst
Gulf Brokers
Trading is risky and your entire investment may be at risk. TC’s available at https://gulfbrokers.com/
*Source: AETOSWire
Contact:
Ziad El-Maadawi, +201227884844
ziad@influence-me.com
+442080689907
support@gulfbrokers.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
